Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

Added 19,066 New Subscribers in 2Q22Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million)         Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million)Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Million)Conference Call to be Held on November 26, 2021, at 8:00 a.m. ET HONG KONG, Nov. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the second quarter and first half of fiscal 2022 on Wednesday, November 24, 2021, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Friday, November 26, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through the

1Q22 Added 19,673 New SubscribersRevenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million)Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million)Operating Income Up 17.3% YoY to RMB156.6 Million ($24.2 Million)Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million)Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET HONG KONG, Aug. 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended June 30

HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results for the first quarter fiscal 2022 on Monday, August 30, 2021, after the market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, August 31, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http:

Added 19,367 New Subscribers in 4Q21Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million)Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million)Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million)Conference Call to be Held on June 29, 2021 at 8:00 a.m. ET HONG KONG, June 28, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2021, ended March 31, 2021. Fourth Quarter Fiscal 2021 Highlight

HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020. Third Quarter Fiscal 2021 Highlights Revenues decreased by 13.1% year-over-year ("YoY") to RMB290.8 million ($44.6 million). New subscribers and accumulated subscriber base were 17,802 and 882,982[1], respectively. Gross profit decreased by 13.1% YoY to RMB245.9 million ($37.7 million). Gross margin remained at 84.6

Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

HONG KONG, Dec. 7, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2020 Annual General Meeting, which was held on December 7, 2020, in Hong Kong S.A.R., China. At the Annual General Meeting, shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2021, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms. Ting Zheng, D

GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

HONG KONG, Aug. 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The filed Form 20-F includes audited financial statements for the fiscal year ended March 31, 2022. The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission's website at http://www.sec.gov and also be found at the Investor Relations section of GCBC's website at http://ir.globalcordbloodcorp.com. About G

HONG KONG, July 6, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO, ", GCBC", or the ", Company", ))), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order") previously obtained by the Company on June 15, 2022 from the Grand Court of the Cayman Islands (the "Court") against Blue Ocean Structure Investment Company Limited ("Blue Ocean") was officially issued by the Court on July 6, 2022. The Order provides, among other things, that: Until further order of the Court, any resolution or resolutions ("Resolutions") that might be passed or purported

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib. Details related to this news can be found via the following Cellenkos news announcement: Cellenkos

Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") and shareholders representing over 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO) today announced the successful approval of all resolutions at the Global Cord Extraordinary General Meeting of Shareholders ("EGM") held today. 104,369,577 shares out of 121,551,075 total outstanding shares of Global Cord voted in the EGM, which represents 85.86 percent of all outstanding shares. The resolutions passed by the shareholders at the EGM are as follows: The removal of the following directors from office of the Company: Ting Zheng, Albert Chen, Mark D. Chen, Jack Chow, Dr. Ken L

HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO, ", GCBC", or the ", Company", ))), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, noticed that on June 3, 2022 Blue Ocean Structure Investment Company Limited (the "Petitioner") issued a notice which purported to convene an extraordinary general meeting of the Company ("Purported EGM") which is due to be held on June 16, 2022. The Company's position is that this EGM has not been validly convened. The Purported EGM was convened without the requisite threshold of 75% having been met. The Company considers it inappropriate to

Blue Ocean Structure Investment Company Ltd.,("Blue Ocean") together with shareholders representing no less than 75% of the outstanding shares of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO) have called an Extraordinary General Meeting of Shareholders ("EGM" or the "Meeting") as allowed by the Company's Articles. The EGM will be held at DLA Piper LLP (US), 1251 Avenue of the Americas, New York, NY 10020-1104, United States of America, on 16 June, 2022 at 9:00 a.m. Eastern Time. To ensure fairness to all participants and in the interest of an orderly and constructive Meeting, Blue Ocean has established Rules of Conduct (the "Rules"). The Rules of Conduct will be

SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13G - Global Cord Blood Corp (0001467808) (Subject)

SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13G - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

SC 13D/A - Global Cord Blood Corp (0001467808) (Subject)

California-based fast-food giant In-N-Out will ban employees from wearing masks in five out of its seven operational states, according to an internal memo that was leaked Friday. In-N-Out employees in California and Oregon can continue to wear masks if they would like, but employees in Arizona, Nevada, Utah, Colorado and Texas will no longer be allowed to wear masks starting Aug. 14.  The policy is being implemented to help promote more effective and clear communication, according to the L.A. Times. If employees need to, they will be able to present a doctor’s note and be able to continue to wear masks.  Read also: DeSantis's 'Lasting Harm' To Disney In Florida Pushes Mouse House To Boost

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: ProPhase Labs (NASDAQ:PRPH) - P/E: 5.74 Aptevo Therapeutics (NASDAQ:APVO) - P/E: 2.84 Global Cord Blood (NYSE:CO) - P/E: 5.11 Jasper Therapeutics (NASDAQ:JSPR) - P

Gainers Golden Sun Education Group Limited (NASDAQ:GSUN) shares surged 92.1% to settle at $52.89 on Friday. Kiromic BioPharma, Inc. (NASDAQ:KRBP) shares climbed 46.4% to close at $0.3750 on Friday. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance. Athersys, Inc. (NASDAQ:ATHX) gained 39.3% to settle at $1.63 after the company announced it entered into amended agreements to extend the exercise period of the warrants that were issued as part of a recent registered direct offering. Snow Lake Resources Ltd. (NASDAQ:LITM) shares climbed 38.3% to settle at $3.18 following n

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock rose 71.7% to $0.44 during Friday's regular session. As of 13:30 EST, Kiromic BioPharma's stock is trading at a volume of 20.8 million, which is 3303.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.9 million. Athersys (NASDAQ:ATHX) shares increased by 53.41% to $1.79. Trading volume for Athersys's stock is 34.4 million as of 13:30 EST. This is 4708.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $547.6 million. Global Cord Blood (NYSE:CO) shares rose 33.78% to $2.97. As of 13:30 EST, this security is trading at a volum

Global Cord Blood's (NYSE:CO) short percent of float has risen 5.26% since its last report. The company recently reported that it has 205 thousand shares sold short, which is 0.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere

Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JPL

Gainers Kiromic BioPharma, Inc. (NASDAQ:KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance. Athersys, Inc. (NASDAQ:ATHX) surged 43% to $1.67 after the company announced it entered into amended agreements to extend the exercise period of the warrants that were issued as part of a recent registered direct offering. Snow Lake Resources Ltd. (NASDAQ:LITM) shares gained 30.4% to $2.9990 following news the company will collaborate with an LG unit to form a North American supply chain for lithium. American Virtual Cloud Technologies, Inc. (

U.S. stocks traded lower this morning, with the Dow Jones dropping around 400 points on Friday. Following the market opening Friday, the Dow traded down 1.34% to 29,673.72 while the NASDAQ fell 1.96% to 10,849.83. The S&P 500 also fell, dropping, 1.75% to 3,692.24. Also check this: Ethereum Rises Above This Major Level, Here Are Other Crypto Movers That Should Be On Your Radar Today Leading and Lagging Sectors Health care shares fell by just 0.7% on Friday. Meanwhile, top gainers in the sector included Cassava Sciences, Inc. (NASDAQ:SAVA), up 35% and Talkspace, Inc. (NASDAQ:TALK) up 17%. In trading on Friday, energy shares dipped by 6.5%. Top Headline The S&P Global services P